| locally advanced NSCLC - maintenance (M) | metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |||
| laNSCLC - M - all population | mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - EGFR mutant | mNSCLC - L2 - PDL1 positive | |
| durvalumab alone | PACIFIC | MYSTIC ... | MYSTIC ... | ARCTIC ... | |
| durvalumab plus osimertinib | CAURAL ... | ||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
